sart3 Antibody

What is SART3 and what are its key structural domains?

SART3, also known as Tip110 or p110, is an RNA-binding protein that contains half-a-tetracopeptide repeats (HAT) in the N-terminus and two RNA recognition motifs (RRMs, RRM1/2) near the C-terminus . The HAT domain plays a critical role in protein-protein interactions, including mediating association with USP15, while the RRM domains are primarily involved in binding RNA targets and certain protein interactions like BARD1 . SART3 demonstrates Loss of Function (LOF) constraint (pLI = 1), indicating its evolutionary importance . The protein is predominantly localized in the nucleus, with particularly high expression observed in malignant tumor cell lines and various cancer tissues .

What are the primary research applications for SART3 antibodies?

SART3 antibodies serve diverse experimental needs across multiple research areas:

• Subcellular localization studies: Detecting nuclear accumulation of SART3 at DNA damage sites and colocalization with repair factors like CtIP and MRE11

• Protein-protein interaction analysis: Investigating SART3 associations with splicing machinery components, DNA repair proteins (BARD1, USP15), and RNA-binding proteins (DDX1)

• RNA-protein interaction studies: Examining SART3 binding to snRNAs (particularly U2, U4, and U6) and miRNAs (like pre-miR-34a)

• DNA damage response research: Monitoring SART3 recruitment to double-strand breaks (DSBs) and its involvement in homologous recombination repair

• Pathological investigations: Studying SART3 mutations linked to intellectual disability and developmental disorders

How does SART3 function differ between normal and cancer cells?

SART3 demonstrates significant differential expression and functional patterns between normal and cancer cells. In cancer contexts, SART3 is highly expressed in the nucleus of malignant tumor cell lines and various cancer tissues . It functions as a potential antigen for cancer immunotherapy, with studies investigating its application in therapeutic approaches . Moreover, SART3 plays a critical role in miR-34a biogenesis, a microRNA with established tumor-suppressive activities that targets cell cycle regulators CDK4/6 and anti-apoptotic factor BCL-2 . Research has shown that many cancers exhibit down-regulation or loss of miR-34a, and SART3's involvement in this pathway suggests a complex role in cancer development . Additionally, SART3 promotes DNA repair mechanisms that can protect cancer cells from damage, potentially affecting their response to chemotherapeutic agents that induce DNA damage .

What are the optimal conditions for SART3 antibody validation?

Validating SART3 antibodies requires comprehensive controls to ensure specificity and reproducibility:

• SART3 knockdown controls: Use siRNA-mediated depletion of SART3 (as demonstrated in studies examining γH2AX levels) to confirm antibody specificity

• Complementation experiments: Test antibody recognition in SART3-depleted cells complemented with wild-type or mutant SART3 constructs, as performed in homologous recombination efficiency studies

• Cross-validation with tagged constructs: Compare endogenous SART3 detection with exogenously expressed tagged versions (GFP-SART3 or similar) to validate recognition patterns

• Domain-specific validation: Use truncated SART3 variants (N-SART3, C-SART3, ΔCC-SART3) to confirm domain-specific antibody binding, especially when studying particular functional regions

• Cell line diversity testing: Validate antibody performance across multiple cell types where SART3 is known to be expressed at different levels

The validation should include multiple experimental modalities (Western blot, immunofluorescence, immunoprecipitation) to ensure consistent recognition across applications.

How should researchers design immunoprecipitation experiments with SART3 antibodies?

Effective immunoprecipitation (IP) experiments with SART3 antibodies require careful consideration of several experimental parameters:

• Buffer optimization: Use buffers that preserve protein-protein and protein-RNA interactions, particularly important when studying SART3's association with splicing factors or DNA repair complexes

• RNase treatment controls: Include RNase A treatment to distinguish RNA-dependent from RNA-independent interactions, as demonstrated in studies of SART3-BARD1 association which was not attenuated by RNase treatment

• Co-IP verification approach:

  • For protein interactions: Perform reverse co-IPs (e.g., immunoprecipitating SNRPA1 to detect co-precipitated SART3)

  • For RNA interactions: Use RT-qPCR to analyze co-purified RNAs (U2, U4, U6 snRNAs or miRNAs)

• DNA damage induction: When studying SART3's role in DNA repair, treat cells with DNA-damaging agents (ETO, CPT, or irradiation) before IP to enhance detection of damage-specific interactions

• Domain-specific interactions: Compare wild-type SART3 with domain mutants to map interaction regions (e.g., determining that the HAT domain mediates U2 snRNP interaction)

What methodological approaches are recommended for studying SART3 in DNA repair contexts?

Research on SART3's role in DNA repair requires specialized methodological approaches:

• DNA damage response markers: Monitor γH2AX levels using SART3 antibodies in conjunction with phospho-specific γH2AX antibodies to assess repair kinetics after damage

• Laser microirradiation: Use laser microirradiation to induce localized DNA damage and track SART3 recruitment using immunofluorescence with SART3 antibodies

• DNA-RNA hybrid detection: Implement DRIP-qPCR (DNA-RNA Immunoprecipitation) with S9.6 antibodies in SART3-depleted cells to measure hybrid accumulation at specific genomic sites

• R-ChIP analysis: Utilize R-ChIP with V5-RNase H1-D210N expression to assess hybrid levels at induced double-strand breaks in control versus SART3-depleted conditions

• HR reporter assays: Apply DR-GFP reporter systems to quantify homologous recombination efficiency when manipulating SART3 levels

• ssDNA visualization: Employ BrdU labeling under non-denaturing conditions to visualize single-stranded DNA generated during end resection, comparing control and SART3-depleted cells

How can researchers investigate SART3's interaction with DNA-RNA hybrids?

Investigating SART3's association with DNA-RNA hybrids requires specialized techniques:

Research has demonstrated that SART3 depletion significantly upregulates the accumulation of DNA-RNA hybrids both in the presence and absence of damage treatment compared to controls . This effect was abolished by RNase H treatment, confirming the specificity of hybrid detection . SART3 is recruited to DSBs in a PARylation- and DNA-RNA hybrid-dependent manner, where it promotes timely removal of these hybrids by recruiting DDX1 .

What methodologies can detect SART3's involvement in splicing regulation?

SART3's role in splicing can be investigated through several sophisticated approaches:

• snRNA association analysis: Immunoprecipitate SART3 and analyze co-purified snRNAs by silver staining in polyacrylamide gels and RT-qPCR, as demonstrated in studies showing SART3's interaction with U2, U4, and U6 snRNAs

• Domain mapping: Use truncated SART3 constructs (N-SART3, C-SART3, etc.) to determine which domains mediate interactions with specific snRNAs or snRNP proteins

• Co-IP of snRNP components: Detect splicing factors like SNRPA1 (U2A′) in SART3 immunoprecipitates to confirm interaction with assembled snRNPs rather than naked snRNAs

• Reciprocal co-IP: Immunoprecipitate snRNP-specific proteins (like SNRPA1) and detect co-precipitated SART3 to verify interactions

• Alternative splicing analysis: Perform RNA-seq in SART3-depleted versus control cells to identify differentially spliced transcripts, potentially revealing targets regulated by SART3

How can SART3 antibodies be used to study its role in miRNA biogenesis?

SART3's unexpected role in miRNA processing can be investigated using the following approaches:

• RNA immunoprecipitation (RIP): Immunoprecipitate SART3 and analyze bound pre-miRNAs (particularly pre-miR-34a) through RT-qPCR

• miRNA expression analysis: Compare miR-34a levels in control versus SART3-depleted cells to assess SART3's impact on mature miRNA production

• Target gene regulation: Monitor expression of miR-34a targets (CDK4/6, BCL-2) after SART3 manipulation to confirm functional consequences

• Interaction domain mapping: Use SART3 truncation mutants to identify which domains interact with pre-miR-34a

• Processing complex analysis: Immunoprecipitate SART3 and detect co-purification of miRNA processing machinery components like Drosha or Dicer

Research has confirmed that pre-miR-34a is enriched upon immunoprecipitation of SART3, suggesting direct interaction . This interaction has been detected across several cancer cell lines, supporting a specific role for SART3 in miR-34a biogenesis .

What are the most common challenges when using SART3 antibodies for immunofluorescence?

Researchers may encounter several challenges when using SART3 antibodies for immunofluorescence:

• Nuclear localization optimization: Since SART3 is predominantly nuclear, optimization of nuclear permeabilization (Triton X-100 concentration and duration) is critical for consistent staining

• Signal-to-noise ratio: Background fluorescence can obscure true signals, particularly when detecting SART3 recruitment to discrete nuclear foci after DNA damage

• Co-localization analysis: When examining SART3 co-localization with factors like CtIP, MRE11, or DNA-RNA hybrids, proper channel separation and bleed-through controls are essential

• Post-translational modification detection: Since SART3 function is regulated by modifications like PARylation, fixation methods must preserve these modifications while maintaining epitope accessibility

• Detection of dynamic recruitment: Capturing transient SART3 recruitment to DNA damage sites requires careful timing of fixation after damage induction

To address these challenges, researchers should implement stringent controls, optimize fixation and permeabilization protocols, use high-quality confocal microscopy, and consider super-resolution techniques for detailed co-localization studies.

How can researchers resolve inconsistent results with SART3 antibodies?

When facing inconsistent results with SART3 antibodies, researchers should systematically address potential sources of variability:

• Epitope accessibility: SART3's involvement in large protein complexes may mask epitopes; try multiple antibodies targeting different regions

• Cell cycle dependence: Since SART3 functions in DNA repair pathways, synchronize cells to eliminate cell cycle variations as a source of inconsistency

• Post-translational modifications: SART3 function is regulated by PARylation and possibly other modifications; consider how experimental conditions might affect these modifications

• Expression level variations: Use quantitative western blotting to establish baseline SART3 levels across experimental conditions

• Technical optimization:

  • For western blotting: Optimize transfer conditions for SART3's molecular weight (~110 kDa)

  • For immunoprecipitation: Test different lysis buffers to preserve interactions of interest

  • For immunofluorescence: Compare multiple fixation methods (paraformaldehyde, methanol, etc.)

What considerations are important when interpreting SART3 antibody data in disease contexts?

Interpreting SART3 antibody data in disease contexts requires careful consideration of several factors:

• Mutational status assessment: Recent research has identified recessive variants in SART3 associated with intellectual disability and developmental delay . When studying patient samples, consider how mutations might affect antibody epitopes or SART3 function

• Expression level correlation: Compare SART3 levels with disease markers and clinical outcomes to establish meaningful correlations

• Cellular context specificity: SART3 functions differently across cell types; interpret data within the appropriate cellular context

• Multi-functional nature: SART3 has diverse roles in splicing, DNA repair, and miRNA biogenesis; consider which function is most relevant to the disease in question

• Cancer-specific considerations: Since SART3 is highly expressed in malignant tumor cells and has been studied as a cancer antigen, distinguish between its potential oncogenic and tumor-suppressive functions when analyzing cancer samples

Research has shown that cancer-associated SART3 mutations (like SART3-R386W) can disrupt specific functions such as DDX1 recruitment to DSBs, highlighting the importance of mutation-specific functional analysis .

How can SART3 antibodies be used to study its role in neurological disorders?

Recent research has identified SART3 variants in individuals with intellectual disability, global developmental delay, and brain anomalies . Researchers can use SART3 antibodies to investigate several aspects of this association:

• Expression pattern analysis: Compare SART3 expression in normal versus patient-derived neural cells using immunohistochemistry or western blotting

• Splicing aberration detection: Use SART3 antibodies in conjunction with splicing factor markers to identify disrupted splicing patterns in neural tissues

• Functional impact assessment: Employ variant-specific SART3 antibodies to detect expression or localization differences of mutant proteins

• Model system validation: Utilize SART3 antibodies in Drosophila models, where knockdown of the SART3 orthologue reveals a conserved role in testicular and neuronal development

• Differentiation studies: Track SART3 expression during neuronal differentiation in iPSCs carrying patient variants to understand developmental impacts

These approaches can help elucidate the mechanism by which SART3 variants contribute to the proposed INDYGON syndrome (Intellectual disability, Neurodevelopmental defects and Developmental delay with 46,XY) .

What methodological approaches can investigate SART3's interaction with USP15 and BARD1?

SART3 has been shown to stimulate USP15-BARD1 interaction to facilitate end resection in DNA repair . Researchers can investigate this complex using:

• Sequential co-immunoprecipitation: First immunoprecipitate with SART3 antibodies, then perform a second IP with USP15 antibodies to isolate the ternary complex

• Domain mapping experiments: Use SART3 truncation constructs to determine which regions mediate interactions with USP15 (HAT domain) and BARD1 (RRM1/2)

• Proximity ligation assay (PLA): Detect in situ protein-protein interactions between SART3, USP15, and BARD1 at DNA damage sites

• FRET/BRET analyses: Employ fluorescence or bioluminescence resonance energy transfer to study dynamic interactions between these proteins

• Impact of DNA damage: Compare complex formation before and after DNA damage induction with agents like CPT, which promotes SART3-BARD1 association

Research has demonstrated that SART3 directly associates with both BARD1 and USP15, with the interaction between SART3 and BARD1 being RNA-independent despite involving the RNA-binding RRM1/2 domain .

How can advanced proteomics approaches enhance SART3 antibody research?

Advanced proteomics can significantly expand our understanding of SART3 functions:

• Post-translational modification mapping: Use immunoprecipitation with SART3 antibodies followed by mass spectrometry to identify phosphorylation, ubiquitination, or PARylation sites that regulate SART3 activity

• Interaction network analysis: Perform quantitative proteomics on SART3 immunoprecipitates under various conditions (normal, DNA damage, splicing inhibition) to build comprehensive interaction networks

• Proximity labeling: Employ BioID or APEX approaches with SART3 fusion proteins to identify transient or weak interactors in living cells

• Domain-specific interactome: Compare interaction profiles of wild-type SART3 versus domain mutants to establish domain-specific functions

• Cross-linking mass spectrometry (XL-MS): Apply this technique to SART3 complexes to determine precise interaction interfaces between SART3 and its binding partners

These approaches could reveal novel functions and regulatory mechanisms for SART3 beyond its established roles in splicing, DNA repair, and miRNA biogenesis.